Belite Bio, Inc (NASDAQ:BLTE – Get Free Report)’s stock price reached a new 52-week high on Thursday . The stock traded as high as $66.49 and last traded at $65.00, with a volume of 55282 shares. The stock had previously closed at $64.98.
Analysts Set New Price Targets
A number of research analysts have commented on BLTE shares. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Belite Bio in a report on Thursday, September 12th. Benchmark restated a “buy” rating and issued a $57.00 price target on shares of Belite Bio in a research note on Tuesday, August 13th.
Check Out Our Latest Stock Analysis on Belite Bio
Belite Bio Trading Up 0.5 %
Belite Bio (NASDAQ:BLTE – Get Free Report) last released its earnings results on Friday, August 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03). Equities analysts anticipate that Belite Bio, Inc will post -1.19 earnings per share for the current year.
Institutional Investors Weigh In On Belite Bio
A hedge fund recently raised its stake in Belite Bio stock. GAMMA Investing LLC increased its position in shares of Belite Bio, Inc (NASDAQ:BLTE – Free Report) by 103.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 871 shares of the company’s stock after acquiring an additional 443 shares during the period. GAMMA Investing LLC’s holdings in Belite Bio were worth $41,000 as of its most recent filing with the Securities and Exchange Commission. 0.53% of the stock is owned by institutional investors.
Belite Bio Company Profile
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
Further Reading
- Five stocks we like better than Belite Bio
- Best Aerospace Stocks Investing
- Texas Roadhouse Stock Steering for New Highs This Year
- Upcoming IPO Stock Lockup Period, Explained
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Trading Halts Explained
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.